Staar Surgical Co: Form 10-Q for the period ended Jun 28, 2024
Filed with the SEC on Aug 7, 2024 and accepted by EDGAR at Aug 7, 2024, 16:06 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2024-06-28. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2024-03-30 to 2024-06-28 | $99.0m | us-gaap:Revenues |
| Revenue | 6 months2023-12-30 to 2024-06-28 | $176.4m | us-gaap:Revenues |
| Cost of revenue | 3 months2024-03-30 to 2024-06-28 | $20.6m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months2023-12-30 to 2024-06-28 | $36.9m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2024-03-30 to 2024-06-28 | $78.4m | us-gaap:GrossProfit |
| Gross profit | 6 months2023-12-30 to 2024-06-28 | $139.4m | us-gaap:GrossProfit |
| Research and development | 3 months2024-03-30 to 2024-06-28 | $14.1m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2023-12-30 to 2024-06-28 | $27.4m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2024-03-30 to 2024-06-28 | $66.5m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months2023-12-30 to 2024-06-28 | $129.8m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2024-03-30 to 2024-06-28 | $11.9m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2023-12-30 to 2024-06-28 | $9.6m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2024-03-30 to 2024-06-28 | $3.0m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2023-12-30 to 2024-06-28 | $4.1m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2024-03-30 to 2024-06-28 | $7.4m | us-gaap:NetIncomeLoss |
| Net income | 6 months2023-12-30 to 2024-06-28 | $4.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2024-03-30 to 2024-06-28 | $0.15 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2023-12-30 to 2024-06-28 | $0.08 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2024-03-30 to 2024-06-28 | $0.15 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2023-12-30 to 2024-06-28 | $0.08 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2024-03-30 to 2024-06-28 | 49,811,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2023-12-30 to 2024-06-28 | 49,529,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2023-12-30 to 2024-06-28 | $11.3m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2023-12-30 to 2024-06-28 | $11.4m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2024-06-28 | $192.8m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2024-06-28 | $383.8m | us-gaap:AssetsCurrent |
| Total assets | At period end2024-06-28 | $512.7m | us-gaap:Assets |
| Current liabilities | At period end2024-06-28 | $66.2m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2024-06-28 | $103.6m | us-gaap:Liabilities |
| Shareholders' equity | At period end2024-06-28 | $409.1m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000950170-24-092753. Last ingested by Listed: Nov 4, 2026, 17:00 ET. Listed shows no prices and gives no investment advice.